TGFB1 and systemic sclerosis: For instance, in systemic sclerosis (SSc), IL6 inhibition reduces dermal thickening and downregulates fibrotic markers (e.g., α-smooth muscle actin) by suppressing the TGF-β/STAT3 axis [39,40].